Nitric oxide therapy in sickle cell disease

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 333-342

  Gladwin, Mark T ^a   Schechter, Alan N ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CELL ADHESION MOLECULE; CYCLIC GMP; HEMOGLOBIN; HYDROXYUREA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUPEROXIDE;

ACUTE CHEST SYNDROME; BLOOD OXYGENATION; BLOOD VESSEL TONE; DRUG MECHANISM; HOMEOSTASIS; HUMAN; LUNG VASOCONSTRICTION; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPERFUSION INJURY; RESPIRATORY DISTRESS; REVIEW; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

EID: 0034778939     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90027-7     Document Type: Article

References (92)

1. Inhaled nitric oxide in sickle cell disease with acute chest syndrome
2. Endothelial dysfunction in patients with sickle cell disease is related to selective impariment of shear stress-mediated vasodilation
3. Renal nitric oxide synthases in transgenic sickle cell mice
4. Ventilation and oxygenation induce endothelial nitric oxide synthase gene expression in the lungs of fetal lambs
5. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options
6. Pathogenesis and treatment of sickle cell disease
7. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery
8. Systemic fat embolism and pulmonary hypertension in sickle cell disease
9. The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease
10. Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis
11. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests
12. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults
13. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
14. The use of nitric oxide in primary pulmonary hypertension
15. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies
16. Oxygen causes fetal pulmonary vasodilation through activation of a calciumdependent potassium channel
17. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation
18. Role of P-selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion
19. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
20. Effect of anemia on intrapulmonary shunt during atelectasis in rabbits
21. Red-blood-cell augmentation of hypoxic pulmonary vasoconstriction: Hematocrit dependence and the importance of nitric oxide
22. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism
23. Effect of transfusion in acute chest syndrome of sickle cell disease
24. Nitrogen metabolism in sickle cell anemia: Free amino acids in plasma and urine
25. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds
26. Mechanisms of stroke in sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition
27. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
28. Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion
29. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia
30. The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment
31. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation
32. Role of circulating nitrite and S-nitrosohemoglobin in the regulation of regional blood flow in humans
33. Nitric oxide (NO) inhalation augments nitrosyl (heme) hemoglobin and SNO-hemoglobin formation in SS patients without changing oxygen affinity
34. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity
35. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea
36. Hypoxic vasoconstriction in blood and plasma perfused lungs
37. Clinical efficacy of prolonged therapy with NO on patients with pulmonary hypertension
38. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo
39. Inhibition of nitric oxide synthase induces acute vaso-occlusion in transgenic sickle mice
40. Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport
41. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical
42. Mechanism for fetal globin gene expression: Role of the soluble guanylate cyclasecGMP-dependent protein kinase pathway
43. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control
44. In vivo production of nitric oxide in rats after administration of hydroxyurea
45. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice
46. Impaired nitric oxidemediated vasodilation in transgenic sickle mouse
47. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin
48. The reaction of deoxy-sickle cell hemoglobin with hydroxyurea
49. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide
50. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R 2 from ribonucleotide reductase with hydroxyurea
51. Sequential nitric oxide measurements during the emergency department treatment of acute vasoocclusive sickle cell crisis
52. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis
53. Beneficial effect of blood transfusion in children with sickle cell chest syndrome
54. Red blood cells play a crucial role in maintaining vascular reactivity to hypoxia in isolated rat lungs
55. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome
56. Arginine therapy: A novel strategy to induce nitric oxide production in sickle cell disease
57. Can we just say NO to sickle cell anemia?
58. Sickle cell disease pathophysiology
59. Levels of fetal hemoglobin necessary for treatment of sickle cell disease
60. Left ventricular filling pressure in sickle cell anemia
61. Hydroxyurea reacts with heme proteins to generate nitric oxide
62. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
63. Vascular endothelial cells synthesize nitric oxide from L-arginine
64. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension
65. Production of nitric oxide metabolites in sickle cell patients after administration of hydroxyurea
66. Sickle cell anemia as an inflammatory disease
67. The acute chest syndrome of sickle cell disease
68. Sparing effect of hemoglobin F and hemoglobin A 2 on the polymerization of hemoglobin S at physiologic ligand saturations
69. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis
70. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
71. The reactions of myoglobin, normal adult hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea
72. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy
73. Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea
74. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
75. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation
76. Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia
77. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
78. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
79. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium
80. Acute chest syndrome in children with sickle cell disease. A retrospective analysis of 100 hospitalized cases
81. Management of sickle cell disease
82. EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin
83. Sickle cell acute chest syndrome: Pathogenesis and rationale for treatment
84. Decrease of very late activation antigen- 4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
85. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent
86. Pulmonary hypertension in sickle cell disease
87. Exposure to shear stress alters endothelial adhesiveness. Role of nitric oxide
88. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM- 1
89. Acute chest syndrome in adult Afro-Caribbean patients with sickle cell disease. Analysis of 81 episodes among 53 patients
90. Pulmonary hypertension and sickle hemoglobinopathy
91. Transfusion management of sickle cell disease
92. Mechanism of action of hydroxyurea